Histological differentiation between sporadic and colitis‐associated intestinal cancer in a nationwide study: A propensity‐score‐matched analysis

Motoi Uchino,Hiroki Ikeuchi,Tatsuki Noguchi,Koji Okabayashi,Kitaro Futami,Shinji Tanaka,Hiroki Ohge,Kazuhiro Watanabe,Michio Itabashi,Kinya Okamoto,Yoshiki Okita,Tsunekazu Mizushima,Yusuke Mizuuchi,Kazutaka Yamada,Yoshifumi Shimada,Yu Sato,Hideaki Kimura,Kenichi Takahashi,Koya Hida,Yusuke Kinugasa,Junji Okuda,Koji Daito,Fumikazu Koyama,Hideki Ueno,Takayuki Yamamoto,Tsunekazu Hanai,Toru Kono,Hirotoshi Kobayashi,Yoichi Ajioka,Kenichi Sugihara,Soichiro Ishihara,Study Group for Inflammatory Bowel Disease Associated Intestinal Cancers of the Japanese Society for Cancer of the Colon and Rectum
DOI: https://doi.org/10.1111/jgh.16496
2024-01-27
Journal of Gastroenterology and Hepatology
Abstract:Background and Aim Colitis‐associated intestinal cancer (CAC) can develop in patients with inflammatory bowel disease; however, the malignant grade of CAC may differ from that of sporadic colorectal cancer (CRC). Therefore, we compared histological findings distinct from cancer stage between CAC and sporadic CRC to evaluate the features of CAC. Methods We reviewed the clinical and histological data collected from a nationwide database in Japan between 1983 and 2020. Patient characteristics were compared to distinguish ulcerative colitis (UC), Crohn's disease (CD), and sporadic CRC. Comparisons were performed by using all collected data and propensity score‐matched data. Results A total of 1077 patients with UC‐CAC, 297 with CD‐CAC, and 136 927 with sporadic CRC were included. Although the prevalence of well or moderately differentiated adenocarcinoma (Tub1 and Tub2) decreased according to tumor progression for all diseases (P
gastroenterology & hepatology
What problem does this paper attempt to address?